 |
|
|
|
|
|
|
|  | Oct 29, 2002
ACTOS® is Today's Most Prescribed Insulin Resistance Reducer for Type 2 Diabetes | |
|
| | Oct 11, 2002
Employers Shifting More Decision-Making and Financial Responsibility of Pharmacy Benefit Plans to Employees | |
|
| | Aug 29, 2002
Takeda Pharmaceuticals North America Names Mark Booth President | |
|
| | May 31, 2002
ACTOS® Improves Glucose Control and Lipid Profiles In People with Type 2 Diabetes Who Use Insulin | |
|
| | Dec 10, 2001
Takeda Pharmaceuticals North America to Expand Sales Force | |
|
| | Nov 15, 2001
Improved Type 2 Diabetes Web Site, ACTOS.com, Encourages Patients to "Take Action" | |
|
| | Oct 18, 2001
TPNA and Eli Lilly and Company Underwrite 2001 Prescription Drug Benefit Cost and Plan Design Survey Report | |
|
| | Sep 19, 2001
Takeda Pharmaceuticals North America Donates to Red Cross Disaster Relief Efforts | |
|
| | Sep 17, 2001
Takeda Pharmaceuticals North America Names Mark Booth Executive Vice President | |
|
| | May 30, 2001
6 Million ACTOS® Prescriptions written in less than two years | |
|
| | May 7, 2001
New Initiative Targets Insulin Resistance | |
|
| | Dec 6, 2000
ACTOS® Passes 3.5 Million Prescriptions | |
|
| | Nov 16, 2000
Study Shows ACTOS® (pioglitazone HCl) Monotherapy Improves Glucose Control in Treatment of Type 2 Diabetes | |
|
| | Sep 14, 2000
TPNA and Eli Lilly and Company Provide Grant to National Diabetes Education Initiative | |
|
| | Jun 10, 2000
Study Findings Show Pioglitazone HCl Improves Glucose Control and Lipid Profiles in Patients with type 2 Diabetes | |
|
| | Jun 5, 2000
New Clinical Study to compare effects of TZD's on patient lipid profiles | |
|
| | May 2, 2000
ACTOS® reaches one million prescription milestone | |
|
| | Apr 5, 2000
ACTOS® is now most prescribed insulin sensitizer by endocrinologists | |
|
| | Mar 22, 2000
ACTOS ® (pioglitazone HCl) is an effective therapy for patients seeking an alternative insulin sensitizer | |
|
| | Jul 16, 1999
TPNA's ACTOS (pioglitazone hcl) Approved for Marketing by FDA for the Treatment of Type 2 Diabetes | |
|
| | Apr 23, 1999
Data showed Takeda's diabetes drug ACTOS™ (pioglitazone hydrochloride) similar placebo on liver safety | |
|
| | Mar 12, 1999
U.S. Food and Drug Administration Grants Priority Review to, Schedules April 1999 Review of, Takeda America Research and Development's ACTOS™ for Treatment of Type 2 Diabetes | |
|
| | Jan 18, 1999
Takeda America Research and Development Center, Inc. Submits NDA for Anti-Diabetic Drug ACTOS™ for Treatment of Type 2 Diabetes | |
|
| | May 25, 1998
Takeda to form independent company in U.S. | |
|
|
